255 related articles for article (PubMed ID: 12398235)
1. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
Díez JJ; Iglesias P
J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
[TBL] [Abstract][Full Text] [Related]
2. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
4. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
5. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
[TBL] [Abstract][Full Text] [Related]
6. The use of octreotide in the treatment of medullary thyroid carcinoma.
Frank-Raue K; Ziegler R; Raue F
Horm Metab Res Suppl; 1993; 27():44-7. PubMed ID: 8330871
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
8. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
Lupoli G; Cascone E; Arlotta F; Vitale G; Celentano L; Salvatore M; Lombardi G
Cancer; 1996 Sep; 78(5):1114-8. PubMed ID: 8780551
[TBL] [Abstract][Full Text] [Related]
10. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
11. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.
Libroia A; Verga U; Di Sacco G; Piolini M; Muratori F
Henry Ford Hosp Med J; 1989; 37(3-4):151-3. PubMed ID: 2576951
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B
Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging in persistent medullary thyroid carcinoma.
Frank-Raue K; Bihl H; Dörr U; Buhr H; Ziegler R; Raue F
Clin Endocrinol (Oxf); 1995 Jan; 42(1):31-7. PubMed ID: 7889629
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide.
Mahler C; Verhelst J; de Longueville M; Harris A
Clin Endocrinol (Oxf); 1990 Aug; 33(2):261-9. PubMed ID: 1977536
[TBL] [Abstract][Full Text] [Related]
16. The role of somatostatin analogs in the management of medullary thyroid carcinoma.
Lupoli GA; Fonderico F; Fittipaldi MR; Colarusso S; Panico A; Cavallo A; Di Micco L; Lupoli G
J Endocrinol Invest; 2003; 26(8 Suppl):72-4. PubMed ID: 15233217
[No Abstract] [Full Text] [Related]
17. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
18. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide].
Frank-Raue K; Raue F; Ziegler R
Med Klin (Munich); 1995 Feb; 90(2):63-6. PubMed ID: 7708002
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
